QOL Analysis Confers Nivolumab Tolerability Versus Placebo for Esophageal, Gastroesophageal Cancer


Similar results with nivolumab and a matched placebo are reported with preliminary health-related quality-of-life data from the CheckMate 577 trial.

Preliminary findings from the phase 3 CheckMate 577 trial (NCT02743494) presented at the 2021 ASCO Gastrointestinal Cancers Symposium show trends toward improved esophageal-specific and health-related quality of life with nivolumab (Opdivo) in patients with esophageal/gastroesophageal cancer, closely correlating with results observed in a placebo group.

“It was previously reported that nivolumab is the first adjuvant therapy to provide a statistically significant and clinically meaningful improvement in disease-free survival versus a placebo in resected esophageal cancer/gastroesophageal junction cancer following neoadjuvant therapy,” said Eric Van Cutsem, MD, PhD, professor of internal medicine at the University of Leuven in Belgium and head of digestive oncology at the University Hospital Gasthuisberg in Leuven, during the virtual presentation.

The primary end point of this study was disease-free survival (DFS), with secondary end points of overall survival (OS) and OS rates at 1, 2, and 3 years. Investigators enrolled 794 patients, of whom 532 were randomly assigned nivolumab and 262 randomly assigned placebo.

To assess health-related quality of life, general- and disease-related symptoms, and functioning disease burden, investigators used the FACT-E and EQ-5D-3L patient-reported outcome questionnaires. The questionaries were administered at baseline, every 4 weeks during the 12-month treatment, and at post-treatment follow-up visits. Completion rates for patient reports at baseline were 95%, and approximately 90% at 12 months.

At baseline, mean health-related quality of life scores were similar in both groups, and both groups saw an increase in these scores after 1 year.

Scores were similar in the nivolumab and placebo groups for the following: FACT-E total score (133.4 vs. 134.03, respectively), EQ-5D Visual Analogue Scale (70.4 vs. 69.1, respectively) and EQ-5D Utility Index (0.82 vs. 0.831, respectively). The investigators also observed similarities in scores for the esophageal cancer subscale (50.2 vs. 50.1).

Increases in these scores occurred from baseline through most time points through 49 weeks in both groups.

“Patients treated with [nivolumab] did not experience a reduction in [health-related] QoL, further supporting clinical data to demonstrate benefit and tolerability for adjuvant [nivolumab] in patients with resected [esophageal cancer/ gastroesophageal junction cancer],” the investigators concluded in their abstract.


Van Cutsem E, Singh P, Cleary JM, et al. Checkmate 577: Health-related quality of life (HRQoL) in a randomized, double-blind phase III study of nivolumab (NIVO) versus placebo (PBO) as adjuvant treatment in patients (pts) with resected esophageal or gastroesophageal junction cancer (EC/GEJC). Presented at: 2021 ASCO Gastrointestinal Cancers Symposium; January 15-17, 2021; virtual. Abstract 167.

Related Videos
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Related Content